Thompson Siegel & Walmsley LLC Boosts Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Thompson Siegel & Walmsley LLC grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 128,039 shares of the company’s stock after buying an additional 13,009 shares during the period. Thompson Siegel & Walmsley LLC owned 0.49% of Eton Pharmaceuticals worth $1,705,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Eton Pharmaceuticals by 230.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock valued at $2,862,000 after buying an additional 149,864 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $147,000. Anchor Capital Advisors LLC acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $805,000. Baader Bank Aktiengesellschaft acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $373,000. Finally, Westside Investment Management Inc. lifted its holdings in shares of Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock worth $3,711,000 after acquiring an additional 33,275 shares during the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ETON shares. B. Riley started coverage on shares of Eton Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd.

Eton Pharmaceuticals Stock Up 6.7 %

Eton Pharmaceuticals stock opened at $15.58 on Friday. The firm has a market cap of $405.87 million, a PE ratio of -70.82 and a beta of 1.37. Eton Pharmaceuticals, Inc. has a 52-week low of $3.03 and a 52-week high of $18.41. The company’s 50 day moving average is $15.28 and its two-hundred day moving average is $11.11.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.